Back to News
Nov 11, 2025 12:00 PM

Vor Biopharma Secures $100 Million Offering After Reporting Efficacy In Kidney Disease Trial

Vor Biopharma Inc. (NASDAQ:VOR) on Tuesday priced an underwritten public offering of 10 million shares at $10.00 per share.

The gross proceeds from the offering are expected to be $100 million.

In addition, Vor Bio has granted the underwriters a 30-day option to purchase up to an additional 1.5 million shares.

See Also: CoreWeave Bulls Should Brace For ‘Wild, Lumpy, Volatile Ride,’

Trial Data

On Saturday, Vor Bio said it achieved the primary endpoint in Stage A of a Phase 3 clinical study in China evaluating telitacicept in adults with IgA nephropathy (IgAN).

The study enrolled 318 adult patients.

In Stage A of the Phase 3 study, telitacicept achieved the primary endpoint of reducing proteinuria, demonstrating a significant reduction in 24-hour ...